MX2023001001A - Agonista del ppar-delta cristalino. - Google Patents

Agonista del ppar-delta cristalino.

Info

Publication number
MX2023001001A
MX2023001001A MX2023001001A MX2023001001A MX2023001001A MX 2023001001 A MX2023001001 A MX 2023001001A MX 2023001001 A MX2023001001 A MX 2023001001A MX 2023001001 A MX2023001001 A MX 2023001001A MX 2023001001 A MX2023001001 A MX 2023001001A
Authority
MX
Mexico
Prior art keywords
crystalline
ppar
delta agonist
agonist
delta
Prior art date
Application number
MX2023001001A
Other languages
English (en)
Inventor
Osama Suleiman
Emma Sharp
Rio Gancedo Susana Del
Cristina Balogh
Rachael Lee
Julie Macrae
Neil Feeder
Original Assignee
Reneo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reneo Pharmaceuticals Inc filed Critical Reneo Pharmaceuticals Inc
Publication of MX2023001001A publication Critical patent/MX2023001001A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se describe en la presente el (E)-2-(4-((3-(4-fluorofenil)-3-(4-(3 -morfolinoprop-1-in-1-il)fenil)alil)oxi)-2-metilfenoxi)acetato de sodio cristalino, los usos de dicho material cristalino en la preparación de composiciones farmacéuticas para el tratamiento de enfermedades o afecciones que se beneficiarían de la administración con un compuesto agonista del PPARd.
MX2023001001A 2020-07-22 2021-07-20 Agonista del ppar-delta cristalino. MX2023001001A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063055235P 2020-07-22 2020-07-22
US202063118431P 2020-11-25 2020-11-25
PCT/US2021/042412 WO2022020376A1 (en) 2020-07-22 2021-07-20 Crystalline ppar-delta agonist

Publications (1)

Publication Number Publication Date
MX2023001001A true MX2023001001A (es) 2023-03-01

Family

ID=79687855

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023001001A MX2023001001A (es) 2020-07-22 2021-07-20 Agonista del ppar-delta cristalino.

Country Status (12)

Country Link
US (3) US11267795B2 (es)
EP (1) EP4185572A4 (es)
JP (1) JP2023534835A (es)
KR (1) KR20230054373A (es)
CN (1) CN116249695A (es)
AU (1) AU2021312855A1 (es)
BR (1) BR112023001048A2 (es)
CA (1) CA3185909A1 (es)
IL (1) IL300000A (es)
MX (1) MX2023001001A (es)
TW (1) TW202219038A (es)
WO (1) WO2022020376A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL300000A (en) 2020-07-22 2023-03-01 Reneo Pharmaceuticals Inc PPAR agonist - crystalline delta
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease
US20240252500A1 (en) 2023-01-29 2024-08-01 Cymabay Therapeutics, Inc. Treatment of chronic pruritic dermatoses
WO2024159048A1 (en) 2023-01-29 2024-08-02 Cymabay Therapeutics, Inc. Treatment of uremic pruritus

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2331336A1 (fr) 1975-11-14 1977-06-10 Rolland Sa A Acides oxy-4,4' bis(phenoxy-2 alcanocarboxyliques), leurs derives et leur application comme medicament
US4920132A (en) 1987-11-03 1990-04-24 Rorer Pharmaceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene D4
US5324743A (en) 1992-12-10 1994-06-28 Eli Lilly And Company Leukotriene B4 antagonists
IL109451A0 (en) 1993-04-29 1994-07-31 Zeneca Ltd Heterocyclic derivatives
US5773469A (en) 1996-06-18 1998-06-30 Ortho Pharmaceutical Corporation Diaryl antimicrobial agents
US6972294B1 (en) 1999-04-20 2005-12-06 Novo Nordisk, A/S Compounds, their preparation and use
CZ20013558A3 (cs) 1999-04-20 2002-05-15 Novo Nordisk A/S Sloučenina, farmaceutický prostředek, způsob léčby, jejich příprava a vyuľití
CA2374263A1 (en) 1999-06-01 2000-12-07 The University Of Texas Southwestern Medical Center Method of treating hair loss using diphenylether derivatives
CN1396904A (zh) 2000-01-28 2003-02-12 诺沃挪第克公司 新颖的化合物、它们的制备和用途
US6569901B2 (en) 2000-01-28 2003-05-27 Novo Nordisk A/S Alkynyl-substituted propionic acid derivatives, their preparation and use
US6555577B1 (en) 2000-01-28 2003-04-29 Novo Nordisk A/S Compounds, their preparation and use
PL357010A1 (en) 2000-01-28 2004-07-12 Novo Nordisk A/S Propionic acid derivatives and their use in the treatment of diabetes and obesity
US6448293B1 (en) 2000-03-31 2002-09-10 Pfizer Inc. Diphenyl ether compounds useful in therapy
EP1276710A1 (en) 2000-04-17 2003-01-22 Novo Nordisk A/S New compounds, their preparation and use
WO2002018355A1 (en) 2000-08-23 2002-03-07 Eli Lilly And Company Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists
US6630504B2 (en) 2000-08-31 2003-10-07 Pfizer Inc. Phenoxyphenylheterocyclyl derivatives as SSRIs
US6869967B2 (en) 2001-07-30 2005-03-22 Novo Nordisk A/S Peroxisome proliferator-activated receptor (PPAR) active vinyl carboxylic acid derivatives
US7067530B2 (en) 2001-07-30 2006-06-27 Novo Nordisk A/S Compounds, their preparation and use
HUP0401575A2 (hu) * 2001-07-30 2004-11-29 Novo Nordisk A/S Új vinil-karbonsav-származékok és ezek alkalmazása cukorbetegség ellen és ezeket tartalmazó gyógyszerkészítmények
EP1414785A1 (en) 2001-07-30 2004-05-06 Novo Nordisk A/S Novel vinyl n-(2-benzoylphenyl)-l-tyrosine derivatives and their use as antidiabetics etc
MXPA04002330A (es) 2001-09-14 2005-04-08 Japan Tobacco Inc Compuestos biarilo ligados.
US7220877B2 (en) 2001-10-17 2007-05-22 Novo Nordisk A/S Compounds, their preparation and use
KR20050036876A (ko) 2001-10-17 2005-04-20 노보 노르디스크 에이/에스 디카르복실산 유도체, 그것의 제제 및 치료에의 사용
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
KR20050057178A (ko) 2002-09-05 2005-06-16 노보 노르디스크 에이/에스 신규 비닐 카르복실산 유도체 및 그들의 치료에의 사용
US7129268B2 (en) 2002-10-28 2006-10-31 Novo Nordisk A/S Peroxisome proliferator activated receptor-active arylene acetic acid derivatives
US20050080115A1 (en) 2002-10-28 2005-04-14 Lone Jeppesen Novel compounds, their preparation and use
BR0315667A (pt) 2002-10-28 2005-09-06 Novo Nordisk As Composto, uso de um composto, composição farmacêutica, e, método para o tratamento
RU2349582C2 (ru) 2002-10-28 2009-03-20 ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Новые соединения и их применение в качестве ppar-модуляторов
EP1745002B1 (en) 2004-05-05 2010-11-03 High Point Pharmaceuticals, LLC Novel compounds, their preparation and use
JP2007536341A (ja) * 2004-05-05 2007-12-13 ノボ　ノルディスク　アクティーゼルスカブ Ｐｐａｒアゴニストとしてのフェノキシ酢酸誘導体
EP1745014B1 (en) 2004-05-05 2011-07-06 High Point Pharmaceuticals, LLC Novel compounds, their preparation and use
ES2449618T3 (es) 2005-06-30 2014-03-20 High Point Pharmaceuticals, Llc Ácidos fenoxiacéticos como activadores de PPAR-delta
CN101356155A (zh) * 2005-12-22 2009-01-28 转化技术制药公司 作为PPAR-δ活化剂的苯氧基乙酸
AU2006327003B2 (en) 2005-12-22 2011-10-06 Vtv Therapeutics Llc Phenoxy acetic acids as PPAR delta activators
US7943612B2 (en) 2006-03-09 2011-05-17 High Point Pharmaceuticals, Llc Compounds that modulate PPAR activity, their preparation and use
EP2029507A1 (en) 2006-06-08 2009-03-04 High Point Pharmaceuticals, LLC Process for preparing phenoxy acetic acid derivatives
US9487493B2 (en) 2013-09-09 2016-11-08 Vtv Therapeutics Llc Use of a PPAR-delta agonist for treating muscle atrophy
US9669288B2 (en) 2014-11-18 2017-06-06 Ags, Llc Method, apparatus, clustered devices, and computer readable storage for conducting a wagering game
IL300000A (en) 2020-07-22 2023-03-01 Reneo Pharmaceuticals Inc PPAR agonist - crystalline delta

Also Published As

Publication number Publication date
EP4185572A4 (en) 2024-09-11
US11267795B2 (en) 2022-03-08
US11713301B2 (en) 2023-08-01
AU2021312855A1 (en) 2023-03-09
US20220024888A1 (en) 2022-01-27
US20240002356A1 (en) 2024-01-04
WO2022020376A1 (en) 2022-01-27
EP4185572A1 (en) 2023-05-31
KR20230054373A (ko) 2023-04-24
JP2023534835A (ja) 2023-08-14
US20220135532A1 (en) 2022-05-05
TW202219038A (zh) 2022-05-16
CA3185909A1 (en) 2022-01-27
IL300000A (en) 2023-03-01
CN116249695A (zh) 2023-06-09
BR112023001048A2 (pt) 2023-04-04

Similar Documents

Publication Publication Date Title
MX2023001001A (es) Agonista del ppar-delta cristalino.
PE20220133A1 (es) Inhibidores del inflamasoma nlrp3
RU2485131C2 (ru) Производные пиридина, замещенные гетероциклическим кольцом и фосфоноксиметильной группой и содержащие их противогрибковые средства
MX2021012542A (es) Proceso para la preparacion de derivados de oxadiazol microbiocidas.
MA58004B1 (fr) Dérivés de pyrazolyle utiles en tant qu'agents anticancéreux
EP4299135A3 (en) Benzisoxazole sulfonamide derivatives
MX2021013472A (es) Moduladores de thr-? y metodos de uso de estos.
JP2017530962A5 (es)
EE05103B1 (et) Famatseutilised kompositsioonid, mis sisaldavad asetidiini derivaate, asetidiini derivaadid ja nende valmistamise meetodid
CN1761487A (zh) 抗炎剂的可分散制剂
NZ542622A (en) Solid pharmaceutical compositions comprising a S1P receptor agonist and a sugar alcohol
MX2023006123A (es) Metodos para elaborar un agonista de ppar-delta.
JP2005536475A5 (es)
MX2021011606A (es) Compuestos dirigidos a prmt5.
WO2020113213A3 (en) Cyclic pantetheine derivatives and uses thereof
MX2022013054A (es) Derivados de imidazolidinona y uso medico de los mismos.
EP4327877A3 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
AU2018272088A8 (en) Crystalline solid forms of salts of N-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-N'-(4-fluorphenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
EA202190302A1 (ru) Соединения 2,6-диаминопиридина
MX2024003738A (es) Formas solidas, composiciones farmaceuticas y preparacion de compuestos de eter macrociclico heteroaromatico.
MX2023013683A (es) Compuestos de isoxazolilo fusionados como inhibidores de lisina acetiltransferasa 6a (kat6a).
WO2020236690A9 (en) Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes
MX2023006504A (es) Compuesto de hidroxamato, metodo de preparacion del mismo y aplicacion del mismo.
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
MX2022006104A (es) Composicion farmaceutica oral que comprende compuesto de carbamato y metodo de preparacion para la misma.